spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

PCI Pharma Services Announces Appointment of Angi Calkins as Chief Human Resources Officer

PCI Pharma Services

Calkins to lead global human resource team for PCI during time of considerable expansion

Philadelphia, PA – January 28, 2019. Leading biopharmaceutical services provider PCI Pharma Services (PCI) is pleased to announce the appointment of Angi Calkins as Senior Vice President and Chief Human Resources Officer. Angi joins PCI as the company experiences considerable growth and global expansion, currently with more than 3,500 associates, spanning eight locations comprised of 20 facilities across three continents. PCI features a broad portfolio of outsourced development and commercialization services focused in drug development and manufacturing, clinical trial supply, as well as commercial contract packaging.

Angi brings significant experience to PCI gained during an impressive career in human resources leadership across multiple and diverse industries including pharmaceutical and life sciences, retail, consumer goods, global HR outsourcing and financial services. Angi joins PCI having served in senior leadership roles at Regeneron Pharmaceuticals, a leading biotechnology company that doubled in size, was recognized each year by Forbes as one of the 100 Greatest Places to Work, and was ranked the industry’s number one Biopharma Employer by Science Magazine during three of her four years in post

Commenting on Angi’s appointment, PCI Chief Executive Officer Salim Haffar noted: “PCI is at a transformative time. We have a celebrated history of partnering with leading pharmaceutical and biotech companies to support bringing their life-saving medicines to patients around the world. Building on those trusted relationships, over the past 12 months we have changed the complexion of the company with acquisitions in key geographies including Dublin, Ireland; Melbourne, Australia; and San Diego, California, bringing new capabilities and greater access to global emerging markets.

“Our company is rich in cutting-edge science and technology, rooted in a dedication to outstanding service and quality. This is achieved through a talented and dedicated workforce. I am very pleased to have Angi join at such an exciting time and am eager to see her insights and leadership help shape the future of the company.”

“I am delighted for this opportunity,” stated Angi. “Across my career I have had opportunities to learn about and excel in both in-house and outsource partnership organizations, and PCI is a uniquely inspiring fit for my background and my passion for people and talent at the heart of great business. I was attracted to PCI by virtue of its outstanding reputation in the industry, its focus on continued investment and global growth, and certainly its singular commitment to delivering outstanding service and industry-leading quality for its clients, ultimately playing a critical role in the lives of our clients’ patients around the world. PCI has demonstrated through its investments and focus on developing a growing global workforce that it is committed to meeting the unique and ever-evolving needs of its clients, both in the short- and the long-term. I am excited to be part of that growth and expansion.”

In addition to key acquisitions in Melbourne, Australia and San Diego, California, PCI recently announced ground-breaking on site expansion at its Rockford, Illinois facility. This complements recently executed site expansions at its European clinical Center of Excellence in Bridgend and its manufacturing Center of Excellence in Tredegar, UK as well as investments at sites in Dublin, Ireland; Hay-on-Wye, UK; and Philadelphia, PA.

For more information, please visit www.pciservices.com

About PCI Pharma Services
The global healthcare industry trusts PCI for the development solutions that increase their products' speed to market and opportunities for commercial success. Only PCI brings the proven experience that comes with more than 50 successful product launches a year and over five decades in the healthcare business. Leading technology and continued investment enables us to address global needs throughout the product life cycle — from preclinical development, clinical investigational studies, commercialization and ongoing supply. Our clients view us as an extension of their business and a collaborative partner, with the shared goal of improving patients' lives. For more information, please visit www.pciservices.com or follow us on Twitter at @PCI_Social.

Contact
Tom Gosschalk / Carrie Lowe at BECG
tom.gosschalk@becg.com / carrie.lowe@becg.com
T: +44 (0)20 3697 7647 / +44 (0)1962 893 913
phone +44 (0)1495 713 633
email sales@pciservices.com
web www.pciservices.com
email Wye Valley Business Park, Hay-on-Wye, HR3 5PG
 
Print this page
Send to a friend
   
spacer
News and Press Releases

Genome & Company Chooses Luina Bio to Supply Innovative Drug Productfor Clinical Trials Programme

Luina Bio, a leading biopharmaceutical manufacturing company in Australia, today announced it will develop and produce an innovative bacterial drug product for Genome & Company to support its clinical trials programme. The relationship signals Luina Bio’s first foray into Asia and further establishes its global leadership in the current Good Manufacturing Practise for microbiome projects.
More info >>


White Papers

Keeping Abreast of the Competitive Environment in Clinical Development

Thomson Reuters

Strategic management of a therapy area requires hard decisions to be made about which programs to invest in and which to let go. Understanding the rapidly changing competitive environment for your drug candidates is a key input into these decisions. It is easy to lose track of the broader picture when a clinical program is in progress and get blindsided by external events.
More info >>

Industry Events

BioTrinity 2019

30 April - 1 May 2019, etc.venues 155 Bishopsgate, London EC2M 3YD

BioTrinity 2019 is taking place from the 30th April – 1stMay at etc.venues 155 Bishopsgatein London. Now in its 13th year, BioTrinity remains the leading Life Sciences Biopartnering and Investment conference in Europe, and generates unrivalled opportunities for life science companies, academics, investors, and major pharmaceutical players to come together to do deals and establish collaborations.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement